Why the study?
Does intravenous nicorandil pretreatment reduce myocardial ischemia during PTCA in patients with angina?
Does intravenous nicorandil pretreatment reduce myocardial ischemia during PTCA in patients with angina?
Intravenous nicorandil pretreatment before PTCA reduces ischemic ST elevation independent of myocardial blood flow, demonstrating pharmacologic preconditioning.
Supports nicorandil pretreatment to reduce periprocedural ischemia in PTCA; confirms pharmacologic preconditioning in RCT.
BACKGROUND: It is not known whether pretreatment with nicorandil, an ATP-sensitive K+ channel (K(ATP)channel) opener, induces a preconditioning effect independent of increased collateral recruitment. METHODS: Forty-four patients with angina who underwent percutaneous transluminal coronary angioplasty (PTCA) to proximal left anterior descending artery (LAD) stenosis were randomly allocated for pretreatment with an intravenous injection of 80 g/kg nicorandil 5 min before initial ballooning (n=22) or saline (n=22). 99mTc tetrofosmin was injected during balloon inflation, quantitative analysis of occlusion images by SPECT was conducted, and the defect severity score (SS) was calculated. An ECG was recorded during the 2-min inflation to calculate the sum of ST elevation (sigmaST). RESULTS: SigmaST levels were significantly reduced in patients with nicorandil pretreatment compared with control patients (control:1.89+/-0.85 mV nicorandil:1.24+/-0.57 mV, p=0.0052). However, no difference was observed in defect severity (control: 79.0+/-32.5, nicorandil: 98.7+/-48.9 ns). A close correlation was observed between SS and sigmaST in both groups (nicorandil group R(2)=0.505, control group R(2)=0.599). A multivariate regression model demonstrated that both defect severity (p<0.0001) and pretreatment with nicorandil (p<0.001) were significantly related to the level of sigmaST, suggesting a cellular protective effect against ischaemia by nicorandil, independent of myocardial blood flow. CONCLUSION: Nicorandil pretreatment resulted in the induction of myocardial preconditioning independent of the severity of ischaemia.
No takes yet. Share an insight, caveat, or question.
Hitoshi Matsuo (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: